Rational Design of a Live Attenuated Dengue Vaccine: 2′-O-Methyltransferase Mutants Are Highly Attenuated and Immunogenic in Mice and Macaques

PLoS Pathogens

Volumn 9, Issue 8, 2013, Pages

  Züst, Roland ^a   Dong, Hongping ^b   Li, Xiao Feng ^c   Chang, David C ^b   Zhang, Bo ^d   Balakrishnan, Thavamalar ^a   Toh, Ying Xiu ^a   Jiang, Tao ^c   Li, Shi Hua ^c   Deng, Yong Qiang ^c   Ellis, Brett R ^e   Ellis, Esther M ^e   Poidinger, Michael ^a   Zolezzi, Francesca ^a   Qin, Cheng Feng ^c   Shi, Pei Yong ^b,f   Fink, Katja ^a  

^a AGENCY FOR SCIENCE   (Singapore)

^b Novartis Institute for Tropical Diseases   (Singapore)

^c BEIJING INSTITUTE OF MICROBIOLOGY AND EPIDEMIOLOGY   (China)

^d WUHAN INSTITUTE OF VIROLOGY   (China)

^e Duke Graduate Medical School   (Singapore)

^f WADSWORTH CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 O METHYLTRANSFERASE; DENGUE VACCINE; IMMUNOGLOBULIN G; INTERFERON; NEUTRALIZING ANTIBODY; UNCLASSIFIED DRUG; VIRUS ENVELOPE PROTEIN; VIRUS ENZYME; VIRUS RNA; LIVE VACCINE; METHYLTRANSFERASE; RNA 2'-O-METHYLTRANSFERASE;

ADAPTIVE IMMUNITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY DEPENDENT ENHANCEMENT; ARTICLE; CD8+ T LYMPHOCYTE; CELL STRAIN BHK; CELL STRAIN HEK293; CONTROLLED STUDY; DENGUE; DENGUE VIRUS 1; DENGUE VIRUS 2; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INNATE IMMUNITY; MALE; METHYLATION; MOSQUITO; MOUSE; NONHUMAN; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; RHESUS MONKEY; SEROCONVERSION; VIREMIA; VIRUS ISOLATION; VIRUS MUTANT; VIRUS NEUTRALIZATION; VIRUS TRANSMISSION; ANIMAL; DENGUE VIRUS; ENZYMOLOGY; GENETICS; HAMSTER; HEK293 CELL LINE; IMMUNOLOGY; MUTANT MOUSE STRAIN; MUTATION;

ANIMALS; CRICETINAE; DENGUE; DENGUE VACCINES; DENGUE VIRUS; HEK293 CELLS; HUMANS; INTERFERON TYPE I; MACACA MULATTA; METHYLTRANSFERASES; MICE; MICE, MUTANT STRAINS; MUTATION; VACCINES, ATTENUATED;

EID: 84883398813     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.1003521     Document Type: Article

References (59)

1. Farrar J, Focks D, Gubler D, Barrera R, Guzman MG, et al. (2007) Towards a global dengue research agenda. Trop Med Int Health 12: 695-699.
2. Gubler DJ, (2002) The global emergence/resurgence of arboviral diseases as public health problems. Arch Med Res 33: 330-342.
3. Alvarez M, Rodriguez-Roche R, Bernardo L, Vazquez S, Morier L, et al. (2006) Dengue hemorrhagic Fever caused by sequential dengue 1-3 virus infections over a long time interval: Havana epidemic, 2001-2002. Am J Trop Med Hyg 75: 1113-1117.
4. Halstead SB, (2007) Dengue. Lancet 370: 1644-1652.
5. Beatty ME, Beutels P, Meltzer MI, Shepard DS, Hombach J, et al. (2011) Health economics of dengue: a systematic literature review and expert panel's assessment. Am J Trop Med Hyg 84: 473-488.
6. Pulendran B, Ahmed R, (2011) Immunological mechanisms of vaccination. Nat Immunol 12: 509-517.
7. Blaney JE Jr, Matro JM, Murphy BR, Whitehead SS, (2005) Recombinant, live-attenuated tetravalent dengue virus vaccine formulations induce a balanced, broad, and protective neutralizing antibody response against each of the four serotypes in rhesus monkeys. J Virol 79: 5516-5528.
8. Gunther VJ, Putnak R, Eckels KH, Mammen MP, Scherer JM, et al. (2011) A human challenge model for dengue infection reveals a possible protective role for sustained interferon gamma levels during the acute phase of illness. Vaccine 29: 3895-3904.
9. Hanley KA, Manlucu LR, Manipon GG, Hanson CT, Whitehead SS, et al. (2004) Introduction of mutations into the non-structural genes or 3′ untranslated region of an attenuated dengue virus type 4 vaccine candidate further decreases replication in rhesus monkeys while retaining protective immunity. Vaccine 22: 3440-3448.
10. Tan BH, Fu J, Sugrue RJ, Yap EH, Chan YC, et al. (1996) Recombinant dengue type 1 virus NS5 protein expressed in Escherichia coli exhibits RNA-dependent RNA polymerase activity. Virology 216: 317-325.
11. Ray D, Shah A, Tilgner M, Guo Y, Zhao Y, et al. (2006) West Nile virus 5′-cap structure is formed by sequential guanine N-7 and ribose 2′-O methylations by nonstructural protein 5. J Virol 80: 8362-8370.
12. Egloff MP, Benarroch D, Selisko B, Romette JL, Canard B, (2002) An RNA cap (nucleoside-2′-O-)-methyltransferase in the flavivirus RNA polymerase NS5: crystal structure and functional characterization. EMBO J 21: 2757-2768.
13. Dong H, Chang DC, Hua MH, Lim SP, Chionh YH, et al. (2012) 2′-O methylation of internal adenosine by flavivirus NS5 methyltransferase. PLoS Pathog 8: e1002642.
14. Daffis S, Szretter KJ, Schriewer J, Li J, Youn S, et al. (2010) 2′-O methylation of the viral mRNA cap evades host restriction by IFIT family members. Nature 468: 452-456.
15. Zust R, Cervantes-Barragan L, Habjan M, Maier R, Neuman BW, et al. (2011) Ribose 2′-O-methylation provides a molecular signature for the distinction of self and non-self mRNA dependent on the RNA sensor Mda5. Nat Immunol 12: 137-143.
16. Chang TH, Liao CL, Lin YL, (2006) Flavivirus induces interferon-beta gene expression through a pathway involving RIG-I-dependent IRF-3 and PI3K-dependent NF-kappaB activation. Microbes Infect 8: 157-171.
17. Loo YM, Fornek J, Crochet N, Bajwa G, Perwitasari O, et al. (2008) Distinct RIG-I and MDA5 signaling by RNA viruses in innate immunity. J Virol 82: 335-345.
18. Pichlmair A, Lassnig C, Eberle CA, Gorna MW, Baumann CL, et al. (2011) IFIT1 is an antiviral protein that recognizes 5′-triphosphate RNA. Nat Immunol 12: 624-630.
19. Fensterl V, Sen GC, (2011) The ISG56/IFIT1 gene family. J Interferon Cytokine Res 31: 71-78.
20. Guo J, Hui DJ, Merrick WC, Sen GC, (2000) A new pathway of translational regulation mediated by eukaryotic initiation factor 3. EMBO J 19: 6891-6899.
21. Liu XY, Chen W, Wei B, Shan YF, Wang C, (2011) IFN-induced TPR protein IFIT3 potentiates antiviral signaling by bridging MAVS and TBK1. J Immunol 187: 2559-2568.
22. Dong H, Zhang B, Shi PY, (2008) Flavivirus methyltransferase: a novel antiviral target. Antiviral Res 80: 1-10.
23. Dong H, Chang DC, Xie X, Toh YX, Chung KY, et al. (2010) Biochemical and genetic characterization of dengue virus methyltransferase. Virology 405: 568-578.
24. Tassaneetrithep B, Burgess TH, Granelli-Piperno A, Trumpfheller C, Finke J, et al. (2003) DC-SIGN (CD209) mediates dengue virus infection of human dendritic cells. J Exp Med 197: 823-829.
25. Brewoo JN, Kinney RM, Powell TD, Arguello JJ, Silengo SJ, et al. (2011) Immunogenicity and efficacy of chimeric dengue vaccine (DENVax) formulations in interferon-deficient AG129 mice. Vaccine 30 (8) (): 1513-20.
26. Huang S, Hendriks W, Althage A, Hemmi S, Bluethmann H, et al. (1993) Immune response in mice that lack the interferon-gamma receptor. Science 259: 1742-1745.
27. Johnson AJ, Roehrig JT, (1999) New mouse model for dengue virus vaccine testing. J Virol 73: 783-786.
28. Schul W, Liu W, Xu HY, Flamand M, Vasudevan SG, (2007) A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 195: 665-674.
29. Anderson KB, Gibbons RV, Edelman R, Eckels KH, Putnak RJ, et al. (2011) Interference and facilitation between dengue serotypes in a tetravalent live dengue virus vaccine candidate. J Infect Dis 204: 442-450.
30. Williams KL, Wahala WM, Orozco S, de Silva AM, Harris E, (2012) Antibodies targeting dengue virus envelope domain III are not required for serotype-specific protection or prevention of enhancement in vivo. Virology 429: 12-20.
31. Yauch LE, Prestwood TR, May MM, Morar MM, Zellweger RM, et al. (2010) CD4+ T cells are not required for the induction of dengue virus-specific CD8+ T cell or antibody responses but contribute to protection after vaccination. J Immunol 185: 5405-5416.
32. Yauch LE, Zellweger RM, Kotturi MF, Qutubuddin A, Sidney J, et al. (2009) A protective role for dengue virus-specific CD8+ T cells. J Immunol 182: 4865-4873.
33. Kamphuis E, Junt T, Waibler Z, Forster R, Kalinke U, (2006) Type I interferons directly regulate lymphocyte recirculation and cause transient blood lymphopenia. Blood 108: 3253-3261.
34. Grant D, Tan GK, Qing M, Ng JK, Yip A, et al. (2011) A single amino acid in nonstructural protein NS4B confers virulence to dengue virus in AG129 mice through enhancement of viral RNA synthesis. J Virol 85: 7775-7787.
35. Balsitis SJ, Williams KL, Lachica R, Flores D, Kyle JL, et al. (2010) Lethal antibody enhancement of dengue disease in mice is prevented by Fc modification. PLoS Pathog 6: e1000790.
36. Coller BA, Clements DE, (2011) Dengue vaccines: progress and challenges. Curr Opin Immunol 23: 391-398.
37. Webster DP, Farrar J, Rowland-Jones S, (2009) Progress towards a dengue vaccine. Lancet Infect Dis 9: 678-687.
38. Murphy BR, Whitehead SS, (2011) Immune response to dengue virus and prospects for a vaccine. Annu Rev Immunol 29: 587-619.
39. Sabchareon A, Wallace D, Sirivichayakul C, Limkittikul K, Chanthavanich P, et al. (2012) Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 380: 1559-67.
40. Lim SP, Sonntag LS, Noble C, Nilar SH, Ng RH, et al. (2011) Small molecule inhibitors that selectively block dengue virus methyltransferase. J Biol Chem 286: 6233-6240.
41. Bentsi-Enchill AD, Schmitz J, Edelman R, Durbin A, Roehrig JT, et al. (2013) Long-term safety assessment of live attenuated tetravalent dengue vaccines: Deliberations from a WHO technical consultation. Vaccine 31: 2603-9.
42. Pierson TC, Xu Q, Nelson S, Oliphant T, Nybakken GE, et al. (2007) The stoichiometry of antibody-mediated neutralization and enhancement of West Nile virus infection. Cell Host Microbe 1: 135-145.
43. Boonnak K, Slike BM, Donofrio GC, Marovich MA, (2013) Human FcgammaRII Cytoplasmic Domains Differentially Influence Antibody-Mediated Dengue Virus Infection. J Immunol 190: 5659-65.
44. Chan KR, Zhang SL, Tan HC, Chan YK, Chow A, et al. (2011) Ligation of Fc gamma receptor IIB inhibits antibody-dependent enhancement of dengue virus infection. Proc Natl Acad Sci U S A 108: 12479-12484.
45. Yamanaka A, Kosugi S, Konishi E, (2008) Infection-enhancing and-neutralizing activities of mouse monoclonal antibodies against dengue type 2 and 4 viruses are controlled by complement levels. J Virol 82: 927-937.
46. Aberle JH, Stiasny K, Kundi M, Heinz FX, (2012) Mechanistic insights into the impairment of memory B cells and antibody production in the elderly. Age (Dordr) 35: 371-81.
47. Galli G, Medini D, Borgogni E, Zedda L, Bardelli M, et al. (2009) Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc Natl Acad Sci U S A 106: 3877-3882.
48. Guzman MG, Alvarez M, Rodriguez-Roche R, Bernardo L, Montes T, et al. (2007) Neutralizing antibodies after infection with dengue 1 virus. Emerg Infect Dis 13: 282-286.
49. Halstead SB, (1974) Etiologies of the experimental dengues of Siler and Simmons. Am J Trop Med Hyg 23: 974-982.
50. Monath TP, Kanesa-Thasan N, Guirakhoo F, Pugachev K, Almond J, et al. (2005) Recombination and flavivirus vaccines: a commentary. Vaccine 23: 2956-2958.
51. Guirakhoo F, Weltzin R, Chambers TJ, Zhang ZX, Soike K, et al. (2000) Recombinant chimeric yellow fever-dengue type 2 virus is immunogenic and protective in nonhuman primates. J Virol 74: 5477-5485.
52. Capeding RZ, Luna IA, Bomasang E, Lupisan S, Lang J, et al. (2011) Live-attenuated, tetravalent dengue vaccine in children, adolescents and adults in a dengue endemic country: randomized controlled phase I trial in the Philippines. Vaccine 29: 3863-3872.
53. Sun W, Cunningham D, Wasserman SS, Perry J, Putnak JR, et al. (2009) Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naive adults. Hum Vaccin 5: 33-40.
54. Lang J, (2009) Recent progress on sanofi pasteur's dengue vaccine candidate. J Clin Virol 46 Suppl 2: S20-24.
55. McBride W, Vasudevan S, (1995) Relationship of a dengue 2 isolate from Townsville,1993, to international isolates. Comm Dis Intelligence 19: 522-523.
56. Zou G, Chen YL, Dong H, Lim CC, Yap LJ, et al. (2011) Functional analysis of two cavities in flavivirus NS5 polymerase. J Biol Chem 286: 14362-14372.
57. Johnson BW, Russell BJ, Lanciotti RS, (2005) Serotype-specific detection of dengue viruses in a fourplex real-time reverse transcriptase PCR assay. J Clin Microbiol 43: 4977-4983.
58. Langmead B, Salzberg SL, (2012) Fast gapped-read alignment with Bowtie 2. Nat Methods 9: 357-359.
59. Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, et al. (2009) The Sequence Alignment/Map format and SAMtools. Bioinformatics 25: 2078-2079.